ATF4 11: 5’ATF4.uORF2.GFP
(Plasmid
#21858)
-
Depositing Lab
-
Publication
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 21858 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepEGFP-N1
-
Backbone manufacturerClontech
- Backbone size w/o insert (bp) 4733
-
Vector typeMammalian Expression
-
Selectable markersNeomycin (select with G418)
Growth in Bacteria
-
Bacterial Resistance(s)Kanamycin, 50 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert nameATF4
-
Alt nameupstream ORF2 of ATF4
-
SpeciesM. musculus (mouse)
-
Insert Size (bp)340
-
Mutationupstream ORF2 (uORF) of ATF4 fused to EGFP
-
Entrez GeneAtf4 (a.k.a. Atf-4, C/ATF, CREB-2, CREB2, TAXREB67)
-
Tag
/ Fusion Protein
- EGFP (C terminal on backbone)
Cloning Information
- Cloning method Restriction Enzyme
- 5′ cloning site HindII (unknown if destroyed)
- 3′ cloning site BamHI (unknown if destroyed)
- 5′ sequencing primer CMV-F
- 3′ sequencing primer EGFP-N (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
These pEGFP-based plasmids have NEOr marker (and not the conventional AMPr marker). They should be propagated in the presence of 30mcg/ml kanamycin (and not on ampicillin)
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
ATF4 11: 5’ATF4.uORF2.GFP was a gift from David Ron (Addgene plasmid # 21858 ; http://n2t.net/addgene:21858 ; RRID:Addgene_21858) -
For your References section:
Translation reinitiation at alternative open reading frames regulates gene expression in an integrated stress response. Lu PD, Harding HP, Ron D. J Cell Biol. 2004 Oct 11. 167(1):27-33. 10.1083/jcb.200408003 PubMed 15479734